This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| National Respiratory and Enteric Virus Surveillance System | |
|---|---|
| Name | National Respiratory and Enteric Virus Surveillance System |
| Formation | 1962 |
| Jurisdiction | United States |
| Headquarters | Atlanta, Georgia |
| Parent agency | Centers for Disease Control and Prevention |
National Respiratory and Enteric Virus Surveillance System
The National Respiratory and Enteric Virus Surveillance System is a United States laboratory-based surveillance network that monitors viral respiratory and enteric pathogens to inform public health action. It aggregates data from clinical, public health, academic, and commercial laboratories to support situational awareness for influenza, respiratory syncytial virus, adenovirus, enteroviruses, and other viral agents. The system interfaces with national and international partners to guide prevention strategies, clinical guidance, and vaccine and antiviral policy.
The system collects and synthesizes diagnostic data from participating laboratories, hospitals, and sentinel sites to produce weekly and seasonal summaries used by agencies such as the Centers for Disease Control and Prevention, Department of Health and Human Services, National Institutes of Health, Food and Drug Administration, and state health departments. It contributes to coordinated responses alongside programs like the Influenza Division (CDC), Global Influenza Surveillance and Response System, World Health Organization, Pan American Health Organization, and regional reference laboratories such as the Public Health Agency of Canada network and the European Centre for Disease Prevention and Control. Key stakeholders include academic centers such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, and commercial laboratories including Quest Diagnostics and LabCorp.
Originating from viral surveillance efforts in the 20th century, the system evolved through collaborations involving the United States Public Health Service, National Institutes of Health, and the State and Territorial Epidemiologists (CSTE). Early laboratory reporting frameworks established in the 1960s and 1970s expanded during outbreaks such as the 1976 swine flu outbreak, 2003 SARS outbreak, 2009 H1N1 pandemic, and the 2019–20 coronavirus pandemic, prompting enhancements in molecular diagnostics and data sharing agreements. Partnerships with academic research programs at Harvard Medical School, University of California, San Francisco, Emory University, and University of Wisconsin drove methodological advances. International coordination with organizations like the World Health Organization and initiatives such as the Global Health Security Agenda further shaped governance and interoperability.
Participating laboratories report antigen, culture, and nucleic acid amplification test results for pathogens including influenza A virus, influenza B virus, respiratory syncytial virus, adenoviridae, and enterovirus D68; reports derive from clinical diagnostic platforms used in institutions like Cleveland Clinic and Seattle Children’s Hospital. Data sources encompass sentinel outpatient clinics, hospital laboratories, commercial diagnostics companies, academic reference labs, and long-term care facility testing programs. Laboratory methods have progressed from viral culture and serology to reverse transcription polymerase chain reaction and multiplexed assays developed by firms such as Roche Diagnostics, Abbott Laboratories, and BioFire Diagnostics, with quality assurance informed by reference centers like the CDC Influenza Division and peer institutions.
Data aggregation employs standardized case definitions and reporting formats compatible with electronic laboratory reporting systems and health information exchanges used by State Health Departments, regional epidemiology units, and federal partners. Weekly surveillance summaries are published to inform clinical guidance from entities such as the Advisory Committee on Immunization Practices, American Academy of Pediatrics, Infectious Diseases Society of America, and hospital infection control programs at centers like Johns Hopkins Hospital. The system’s outputs feed into models developed by researchers at Columbia University, Imperial College London, and University of Washington for burden estimation and forecasting, and support situational reports coordinated with Federal Emergency Management Agency during public health emergencies.
Surveillance outputs inform vaccine strain selection processes led by World Health Organization consultations and national immunization recommendations by the Advisory Committee on Immunization Practices, and guide antiviral stockpiling policies involving the Strategic National Stockpile and Department of Defense medical readiness planners. Data support clinical guidelines promulgated by Centers for Disease Control and Prevention, Infectious Diseases Society of America, and specialty societies such as the American Thoracic Society and the Society for Healthcare Epidemiology of America. Historical surveillance has influenced responses to events including the 2009 H1N1 pandemic, seasonal influenza vaccination campaigns, and targeted mitigation during outbreaks like the 2014–2016 Ebola epidemic where respiratory and enteric surveillance intersected with broader outbreak control.
The system is coordinated by laboratories and surveillance units within the Centers for Disease Control and Prevention with contributions from state and local health departments, academic partners, and private laboratories. Funding sources include congressional appropriations to CDC, programmatic grants from the National Institutes of Health, cooperative agreements with state health departments, and contracts with commercial partners. Collaborative governance involves advisory input from professional organizations such as the Council of State and Territorial Epidemiologists, Association of Public Health Laboratories, and academic consortia at institutions like Yale School of Public Health and Johns Hopkins Bloomberg School of Public Health.
Limitations include variable laboratory participation across jurisdictions, reporting delays that affect real-time situational awareness, and heterogeneity in testing platforms used by entities like Quest Diagnostics and hospital laboratories, complicating comparability. The system must adapt to emerging pathogens such as novel coronaviruses discovered during the 2019–20 coronavirus pandemic and to shifts in healthcare utilization influenced by policy decisions at the Department of Health and Human Services. Data completeness and representativeness are also affected by disparities in access to care in regions served by institutions like Rural Health Clinics and by changes in diagnostic market forces involving companies such as Thermo Fisher Scientific and BD (Becton, Dickinson and Company). Ongoing challenges include sustaining funding, ensuring interoperability with electronic health records from vendors like Epic Systems and Cerner Corporation, and integrating genomic surveillance capacity demonstrated by collaborations with labs at Broad Institute and Centers for Disease Control and Prevention Division of Viral Diseases.
Category:Public health surveillance in the United States